Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorJoseph Sferra
About this trial
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
Eligibility criteria
Qualifiers
Diagnosis of primary hyperparathyroidism
Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study
Patient desires surgical intervention for treatment of PHPT
No contraindications to 99mTC-Sestamibi
Disqualifiers
Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary
Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT
Allergy to calcitonin
Hypocalcemia (contraindication to calcitonin)
Trial design
Treatments tested in this trial
- Calcitonin
Treatment groups
37 Participants
are divided into 1 treatment groupSponsors and collaborators
Joseph Sferra
Lead sponsor
ProMedica Health System
Sponsor institution
University of Toledo Health Science Campus
Collaborator
Source ClinicalTrials.gov